1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with or without pembrolizumab maintenance therapy in patients with lymphoma
    Journal Article

    Merryman, R. W.; Redd, R.; Jeter, E.; Wong, J. L.; McHugh, K.; Reynolds, C.; Nazzaro, M.; Varden, A.; Brown, J. R.; Crombie, J. L.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
    Review

    Morris, E. C.; Neelapu, S. S.; Giavridis, T.; Sadelain, M.
    Nature Reviews Immunology (2022)

    Fulltext@MSK | Save
  • Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: A phase 1 trial
    Journal Article

    Boulad, F.; Maggio, A.; Wang, X.; Moi, P.; Acuto, S.; Kogel, F.; Takpradit, C.; Prockop, S.; Mansilla-Soto, J.; Cabriolu, A.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • GCN2 kinase activation by ATP-competitive kinase inhibitors
    Journal Article

    Tang, C. P.; Clark, O.; Ferrarone, J. R.; Campos, C.; Lalani, A. S.; Chodera, J. D.; Intlekofer, A. M.; Elemento, O.; Mellinghoff, I. K.
    Nature Chemical Biology (2022)

    Fulltext@MSK | Save
  • Engineering CAR-T cells to activate small-molecule drugs in situ
    Journal Article

    Gardner, T. J.; Lee, J. P.; Bourne, C. M.; Wijewarnasuriya, D.; Kinarivala, N.; Kurtz, K. G.; Corless, B. C.; Dacek, M. M.; Chang, A. Y.; Mo, G.; more...
    Nature Chemical Biology (2022)

    Fulltext@MSK | Save
  • A comprehensive review of the impact of obesity on plasma cell disorders
    Review

    Parikh, R.; Tariq, S. M.; Marinac, C. R.; Shah, U. A.
    Leukemia (2022)

    Fulltext@MSK | Save
  • Machine learning-based prediction of 1-year mortality for acute coronary syndrome
    Journal Article

    Hadanny, A.; Shouval, R.; Wu, J.; Gale, C. P.; Unger, R.; Zahger, D.; Gottlieb, S.; Matetzky, S.; Goldenberg, I.; Beigel, R.; more...
    Journal of Cardiology (2022)

    Fulltext@MSK | Save
  • Current treatment of chronic lymphocytic leukemia: The diminishing role of chemoimmunotherapy
    Review

    Roeker, L. E.; Thompson, M.; Mato, A. R.
    Drugs (2022)

    Fulltext@MSK | Save
  • A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients
    Research Letter

    Tan, C. R.; Estrada-Merly, N.; Landau, H.; Lekakis, L.; Banerjee, R.; Mian, H.; Usmani, S. Z.; Hanbali, A.; Lazarus, H. M.; Kyle, R. A.; more...
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save
  • The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
    Journal Article

    Horwitz, S.; O'Connor, O. A.; Pro, B.; Trümper, L.; Iyer, S.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save